Migalastat provided clinical benefit to patients with Fabry disease and amenable variants, regardless of disease severity.
No takes yet. Share an insight, caveat, or question.
Germain et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: